STOCK TITAN

SVRA sets underwritten deal; 30-day option for 4,642,857 shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Savara Inc. announced an underwritten offering, agreeing to issue and sell 23,809,524 shares of common stock at $4.20 per share and pre-funded warrants to purchase 7,142,857 shares with a $0.001 exercise price, priced at $4.199 per warrant. The company also granted the underwriters a 30‑day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions.

The transaction was conducted under Savara’s effective Form S-3 shelf, with closing expected on October 31, 2025, subject to customary conditions. Jefferies LLC and Piper Sandler & Co. acted as representatives of the several underwriters. Legal opinions related to the issuance were provided by Polsinelli PC.

Positive

  • None.

Negative

  • None.

Insights

Primary equity financing with pre-funded warrants; neutral impact.

Savara priced a firm-commitment deal comprising common shares at $4.20 and pre-funded warrants priced at $4.199 with a nominal $0.001 exercise price. The structure allows immediate capital from shares and near-equivalent cash from pre-funded warrants, which are typically used to accommodate ownership limits while aligning economics with common stock.

The underwriters received a 30-day option for up to 4,642,857 additional shares, which can increase gross proceeds if exercised. The offering uses the company’s effective Form S-3, and closing is expected on October 31, 2025, subject to customary conditions.

Key factors include actual allocation between shares and pre-funded warrants and whether the over-allotment option is exercised. Subsequent disclosures may detail net proceeds and intended uses.

Savara Inc false 0001160308 0001160308 2025-10-29 2025-10-29
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

 

 

SAVARA INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-32157   84-1318182

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1717 Langhorne Newtown Road Suite 300
Langhorne, PA 19047
(Address of principal executive offices, including zip code)

(512) 614-1848

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   SVRA   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 1.01.

Entry into a Material Definitive Agreement.

On October 29, 2025, Savara Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (i) an aggregate of 23,809,524 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants to purchase an aggregate of 7,142,857 shares of Common Stock with an exercise price of $0.001 per share (the “Pre-Funded Warrants”), to the Underwriters in an underwritten offering (the “Offering”). The public offering price of the Shares is $4.20 per share, and the offering price of the Pre-Funded Warrants is $4.199 per Pre-Funded Warrant, which represents the per share offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant. The Company also granted the underwriters a 30-day option to purchase up to an additional 4,642,857 shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on October 31, 2025, subject to the satisfaction of customary closing conditions.

The Offering was made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-279274), which was previously filed with the Securities Exchange Commission (the “SEC”) on May 9, 2024 and declared effective on May 21, 2024. A prospectus supplement relating to the Offering will be filed with the SEC.

The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to the Underwriting Agreement. The foregoing description of the material terms of the Underwriting Agreement and the Pre-Funded Warrants does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement and the form of Pre-Funded Warrant. Copies of the Underwriting Agreement and the form of Pre-Funded Warrant are filed as Exhibit 1.1 and 4.1 to this Current Report on Form 8-K, respectively, and each is incorporated herein by reference.

Polsinelli PC, counsel to the Company, delivered an opinion as to legality of the issuance and sale of the securities in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

 

Item 8.01.

Other Events.

A copy of the press release announcing the pricing of the offering is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.
   Description
 1.1    Underwriting Agreement, dated October 29, 2025, by and among Savara Inc., Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters named therein.
 4.1    Form of Pre-Funded Warrant
 5.1    Opinion of Polsinelli PC.
23.1    Consent of Polsinelli PC (included in Exhibit 5.1).
99.1    Press Release of Savara Inc., dated October 29, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 30, 2025      

SAVARA INC.

a Delaware corporation

    By:  

/s/ Dave Lowrance

      Dave Lowrance
      Chief Financial & Administrative Officer

FAQ

What did Savara (SVRA) announce?

Savara agreed to sell 23,809,524 common shares at $4.20 and pre-funded warrants to purchase 7,142,857 shares priced at $4.199 with a $0.001 exercise price.

Is there an over-allotment option in the Savara (SVRA) offering?

Yes. The underwriters have a 30-day option to buy up to 4,642,857 additional shares at the public offering price, less fees.

When is the Savara (SVRA) offering expected to close?

Closing is expected on October 31, 2025, subject to customary closing conditions.

Under what registration was the Savara (SVRA) offering made?

The offering was made under Savara’s effective Form S-3 shelf (File No. 333-279274).

Who are the underwriters for Savara (SVRA)?

Jefferies LLC and Piper Sandler & Co. served as representatives of the several underwriters.

What are the prices and exercise terms of the pre-funded warrants?

Pre-funded warrants were priced at $4.199 per warrant and are exercisable for common stock at $0.001 per share.
Savara Inc

NASDAQ:SVRA

View SVRA Stock Overview

SVRA Rankings

SVRA Latest News

SVRA Latest SEC Filings

SVRA Stock Data

1.13B
186.58M
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN